After sequential therapy with first and third generation EGFR-TKIs, a patient acquired EGFR G719A mutation and responded to afatinib, and then, acquired EGFR T790M mutation when developed resistance to afatinib:a case report
NSCLC patients who had sensitive EGFR mutation had great pos sibility to get benefit from EGFR-TKIs. But this efficacy was re lied on related EGFR mutation, if related EGFR mutation changed, resistance would happened. In our report, we did next generation sequencing(NGS) each time the patient had progression.